NCT03229694 is a Phase 4 clinical trial of Tracleer 125Mg Tablet in Tourniquets, sponsored by Xuzhou Medical University.

Who is sponsoring NCT03229694?

NCT03229694 is sponsored by Xuzhou Medical University.

What drugs are being tested in NCT03229694?

Interventions in NCT03229694: Tracleer 125Mg Tablet, Placebo.

What condition does NCT03229694 study?

NCT03229694 studies Tourniquets, Hypertension, Bosentan.

Is NCT03229694 still recruiting?

NCT03229694 is currently status unknown. Last updated 25 July 2017.

Last reviewed 2017-07-25 · How we verify

NCT03229694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

the Effect of Tracleer on Tourniquet-associated Hypertension

Status unknown Phase 4 Last updated 25 July 2017

What this trial tests

Phase 4 trial testing Tracleer 125Mg Tablet in Tourniquets in 80 participants. Status unknown.

Timeline

1 August 2017

Primary endpoint
1 April 2018

1 May 2018

Quick facts

Lead sponsor	Xuzhou Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	80
Start date	1 August 2017
Primary completion	1 April 2018
Estimated completion	1 May 2018
Sites	1 location across China

Drugs / interventions tested

Tracleer 125Mg Tablet — full drug profile →
Placebo

Conditions studied

Tourniquets — all drugs for Tourniquets →
Hypertension — all drugs for Hypertension →
Bosentan — all drugs for Bosentan →

Sponsor

Xuzhou Medical University

Who can join

Adults 18 to 65, any sex, with Tourniquets or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tourniquet is widely used in orthopedic surgery. However, prolonged tourniquet inflation may cause a gradual rise in blood pressure, which named as tourniquet-associated hypertension. Thus, to effectively prevent the tourniquet related hemodynamic responses is important for patients receiving limb surgery. Tracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. Tracleer can also be used to treat retistant hypertension. At present trial, the investigators are going to investigate the effect of Tracleer on tourniquet-associated hypertension during total knee arthroplasty.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neuronal Endothelin a Receptor Mediates Experimental and Clinical Vascular Pain through an Endothelial-Neural Axis.
Jiang ZJ, Mu D, Liu S, Jing PB, et al · · 2025 · cited 4× · PMID 40810652 · DOI 10.1002/advs.202512375

Verify or expand the search:

Other trials of Tracleer 125Mg Tablet

Trials testing the same drug.

NCT04101370 — Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Sub · Phase 1 · completed

Other recruiting trials for Tourniquets

Currently open trials in the same condition.

NCT07412925 — Impact Tourniquet Conservative Placenta Accreta Neonatal APGAR · NA · recruiting

Other Xuzhou Medical University trials

Trials by the same sponsor.

NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
NCT07280793 — CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
NCT07070960 — A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible · NA · not yet recruiting
NCT07070934 — CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? · Phase 2 · not yet recruiting
NCT06963866 — Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03229694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuzhou Medical University
Last refreshed: 25 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03229694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing